Literature DB >> 17909019

Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms.

Maria Ester Bernardo1, Nadia Zaffaroni, Francesca Novara, Angela Maria Cometa, Maria Antonietta Avanzini, Antonia Moretta, Daniela Montagna, Rita Maccario, Raffaella Villa, Maria Grazia Daidone, Orsetta Zuffardi, Franco Locatelli.   

Abstract

Significant improvement in the understanding of mesenchymal stem cell (MSC) biology has opened the way to their clinical use. However, concerns regarding the possibility that MSCs undergo malignant transformation have been raised. We investigated the susceptibility to transformation of human bone marrow (BM)-derived MSCs at different in vitro culture time points. MSCs were isolated from BM of 10 healthy donors and propagated in vitro until reaching either senescence or passage (P) 25. MSCs in the senescence phase were closely monitored for 8 to 12 weeks before interrupting the cultures. The genetic characterization of MSCs was investigated through array-comparative genomic hybridization (array-CGH), conventional karyotyping, and subtelomeric fluorescent in situ hybridization analysis both before and after prolonged culture. MSCs were tested for the expression of telomerase activity, human telomerase reverse transcriptase (hTERT) transcripts, and alternative lengthening of telomere (ALT) mechanism at different passages. A huge variability in terms of proliferative capacity and MSCs life span was noted between donors. In eight of 10 donors, MSCs displayed a progressive decrease in proliferative capacity until reaching senescence. In the remaining two MSC samples, the cultures were interrupted at P25 to pursue data analysis. Array-CGH and cytogenetic analyses showed that MSCs expanded in vitro did not show chromosomal abnormalities. Telomerase activity and hTERT transcripts were not expressed in any of the examined cultures and telomeres shortened during the culture period. ALT was not evidenced in the MSCs tested. BM-derived MSCs can be safely expanded in vitro and are not susceptible to malignant transformation, thus rendering these cells suitable for cell therapy approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909019     DOI: 10.1158/0008-5472.CAN-06-4690

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  243 in total

1.  Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate.

Authors:  A Poloni; G Maurizi; F Serrani; S Mancini; G Discepoli; A L Tranquilli; R Bencivenga; P Leoni
Journal:  Cell Prolif       Date:  2011-12-14       Impact factor: 6.831

Review 2.  Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.

Authors:  Emanuela Binello; Isabelle M Germano
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

Review 3.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

4.  Quality of Cell Products: Authenticity, Identity, Genomic Stability and Status of Differentiation.

Authors:  Kurt E J Dittmar; Meike Simann; Nadia Zghoul; Oliver Schön; Wilhelm Meyring; Horst Hannig; Lars Macke; Wilhelm G Dirks; Konstantin Miller; Henk S P Garritsen; Werner Lindenmaier
Journal:  Transfus Med Hemother       Date:  2010-03-08       Impact factor: 3.747

Review 5.  Mesenchymal stem cells as feeder cells for pancreatic islet transplants.

Authors:  Valeria Sordi; Lorenzo Piemonti
Journal:  Rev Diabet Stud       Date:  2010-08-10

6.  Defining the probability that a cell therapy will produce a malignancy.

Authors:  Darwin J Prockop
Journal:  Mol Ther       Date:  2010-07       Impact factor: 11.454

7.  Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells.

Authors:  Benjamin L Larson; Joni Ylostalo; Ryang H Lee; Carl Gregory; Darwin J Prockop
Journal:  Tissue Eng Part A       Date:  2010-07-13       Impact factor: 3.845

8.  A comprehensive study on optimization of proliferation and differentiation potency of bone marrow derived mesenchymal stem cells under prolonged culture condition.

Authors:  M Dhanasekaran; S Indumathi; R P Lissa; R Harikrishnan; J S Rajkumar; D Sudarsanam
Journal:  Cytotechnology       Date:  2012-06-23       Impact factor: 2.058

9.  Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints.

Authors:  Jaewoo Pak; Jae-Jin Chang; Jung Hun Lee; Sang Hee Lee
Journal:  BMC Musculoskelet Disord       Date:  2013-12-01       Impact factor: 2.362

10.  Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.

Authors:  Moa Fransson; Elena Piras; Hao Wang; Joachim Burman; Ida Duprez; Robert A Harris; Katarina LeBlanc; Peetra U Magnusson; Eva Brittebo; Angelica S I Loskog
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.